This cross-sectional study uses time-series data to evaluate the administration of bamlanivimab-etesevimab and casirivimab-imdevimab monoclonal antibody treatments for SARS-CoV-2 infection after the US Food and Drug Administration deauthorized their use in early 2022.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9425149 | PMC |
| http://dx.doi.org/10.1001/jamanetworkopen.2022.28997 | DOI Listing |
Publication Analysis
Top Keywords
food drug
8
drug administration
8
administration
4
administration anti-sars-cov-2
4
anti-sars-cov-2 monoclonal
4
monoclonal antibodies
4
antibodies food
4
administration deauthorization
4
deauthorization cross-sectional
4
cross-sectional study
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!